BioSpace News Archive

Feb. 11, 2020 13:00 UTC Funds to support expanding global menu and further U.S. clinical trial activities SYDNEY--( BUSINESS WIRE )-- SpeeDx Pty Ltd, the developer of innovative clinical diagnostics to support improved patient outcomes, today announced it has raised $15 million in additional series B equity investment from U.S.-based Northpond Ventures. This investment comes with a company value uptick of 21.22%. This press release features multimedia. View the full rele

The Virtual Care Task Force, a collaboration of the Canadian Medical Association, the Royal College of Physicians and Surgeons of Canada and the College of Family Physicians of Canada, released its recommendations for enabling and expanding the implementation of virtual care in Canada.

Dallas-based healthcare AI startup DocSynk is pleased to announce bridge funding from Chicago-based PE firm Colosseum Group.

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the fiscal year ended December 31, 2019, and provided a business update.

PEDMARK™ is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children

T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease, announced the initiation of screening and enrollment for the PIONEER Phase 2 clinical trial for its product candidate T3D-959.

Working women caring for children experience loneliness, isolation and stress at far greater rates than others and are looking to their employers to help them better manage these issues, according to the results of a new survey from WebMD Health Services.

Axonics Modulation Technologies, Inc. announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference, Tuesday, February 25, at 3:30pm ET in New York City, and will be available for meetings with institutional investors.

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced Matthew Oberley, M.D., Ph.D., has been appointed Executive Medical Director.

Beam Therapeutics Inc. announced the pricing of its initial public offering of 10,588,236 shares of common stock at a public offering price of $17.00 per share.